DalsnaFinance Account

Boston Scientific $BSX

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts

Create a scorecard

$45.58

+0.53 (+1.18%)

As of Oct 20, 2026, 5:56 PM EDT · cached

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 28, 2026, the first target we tracked for BSX.

Key facts

52-week range (closes): $41.58 – $104.98 Lowest close Oct 7, 2026, highest Nov 13, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings: Oct 28, 2026, before the open · EPS forecast $0.76 Nasdaq earnings calendar, as of Oct 20, 2026
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Feb 24, 1995 · All S&P 500 changes
Analyst coverage: 5 open price targets from 5 firms: Bernstein, BTIG, Stifel, TD Cowen, UBS Approved targets tracked here; see the analyst section below

Boston Scientific (BSX) is trading up at $45.58 (+1.18%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on BSX

Current price targets from 5 firms average $60.8, median $60, ranging from $54 to $74 — the average is 33% above the current $45.6. Each is tracked to its date and scored the same way a member's call is.

Bernstein $42.4 → $54 by Oct 2027 Outperform Oct 5, 2026 via Investing.com · Bernstein's track record
TD Cowen $47.8 → $56 by Sep 2027 Buy Sep 4, 2026 via Investing.com · TD Cowen's track record
Stifel $48.2 → $60 by Aug 2027 Buy Aug 26, 2026 via Investing.com · Stifel's track record
BTIG $46 → $60 by Jul 2027 Buy Jul 29, 2026 via Investing.com · BTIG's track record
UBS $46.1 → $74 by Jul 2027 Buy Jul 28, 2026 via Investing.com · UBS's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Boston Scientific revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Boston Scientific annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$9.08B	$9.05B	$9.82B	$10.7B	$9.91B	$11.9B	$12.7B	$14.2B	$16.7B	$20.1B
Growth (year over year)	+12.5%	−0.3%	+8.6%	+9.3%	−7.7%	+19.9%	+6.7%	+12.3%	+17.6%	+19.9%
Gross profit	$5.96B	$6.46B	$7.01B	$7.62B	$6.45B	$8.18B	$8.73B	$9.90B	$11.5B	$13.9B
Gross margin	65.7%	71.3%	71.4%	71.0%	65.0%	68.8%	68.8%	69.5%	68.6%	69.0%
Operating income	$447.0M	$1.28B	$1.51B	$1.52B	−$80.0M	$1.20B	$1.65B	$2.34B	$2.60B	$3.61B
Operating margin	4.9%	14.2%	15.3%	14.1%	−0.8%	10.1%	13.0%	16.5%	15.5%	18.0%
Net income	$347.0M	$104.0M	$1.67B	$4.70B	−$115.0M	$985.0M	$642.0M	$1.57B	$1.85B	$2.90B
Net margin	3.8%	1.1%	17.0%	43.8%	−1.2%	8.3%	5.1%	11.0%	11.1%	14.4%
EPS (diluted)	$0.25	$0.08	$1.19	$3.33	−$0.08	$0.69	$0.45	$1.07	$1.25	$1.94
Balance sheet
Cash and equivalents	$196.0M	$188.0M	$146.0M	$217.0M	$1.73B	$1.93B	$928.0M	$865.0M	$414.0M	$1.97B
Total assets	$18.1B	$19.0B	$21.0B	$30.6B	$30.8B	$32.2B	$32.5B	$35.1B	$39.4B	$43.7B
Total liabilities	$11.4B	$12.0B	$12.3B	$16.7B	$15.5B	$15.6B	$14.9B	$15.6B	$17.4B	$19.2B
Long-term debt	$5.42B	$3.81B	$4.80B	$8.59B	$9.13B	$8.80B	$8.91B	$8.57B	$8.97B	$11.1B
Shareholders' equity	$6.73B	$7.01B	$8.73B	$13.9B	$15.3B	$16.6B	$17.6B	$19.3B	$21.8B	$24.2B
Cash flow
Operating cash flow	$1.18B	$1.43B	$310.0M	$1.84B	$1.51B	$1.87B	$1.53B	$2.50B	$3.44B	$4.53B
Capital expenditure	$376.0M	$319.0M	$316.0M	$461.0M	$376.0M	$554.0M	$588.0M	$711.0M	$790.0M	$876.0M
Free cash flow	$806.0M	$1.11B	−$6.00M	$1.38B	$1.13B	$1.32B	$938.0M	$1.79B	$2.65B	$3.66B
Dividends paid	—	—	$0	$0	$28.0M	$55.0M	$55.0M	$28.0M	$0	—
Share buybacks	$0	—	$0	$0	$535.0M	$0	$0	—	—	—

RevenueNet incomeNet margin (right axis, %)

Boston Scientific quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$4.21B	$4.56B	$4.66B	$5.06B	$5.07B	$5.29B	$5.20B	$5.44B
Growth (year over year)	+19.3%	+22.5%	+20.9%	+22.8%	+20.3%	+15.8%	+11.6%	+7.5%
Gross profit	$2.90B	$3.10B	$3.21B	$3.42B	$3.54B	$3.68B	$3.61B	$3.85B
Gross margin	68.8%	67.8%	68.8%	67.7%	69.9%	69.6%	69.5%	70.7%
Operating income	$733.0M	$675.0M	$921.0M	$819.0M	$1.05B	$825.0M	$1.10B	$1.18B
Operating margin	17.4%	14.8%	19.8%	16.2%	20.7%	15.6%	21.2%	21.6%
Net income	$469.0M	$565.0M	$674.0M	$797.0M	$755.0M	$672.0M	$1.34B	$907.0M
Net margin	11.1%	12.4%	14.5%	15.7%	14.9%	12.7%	25.8%	16.7%
EPS (diluted)	$0.32	$0.38	$0.45	$0.53	$0.51	$0.45	$0.90	$0.61
Balance sheet
Cash and equivalents	$2.50B	$414.0M	$725.0M	$534.0M	$1.27B	$1.97B	$1.45B	$539.0M
Total assets	$38.1B	$39.4B	$40.1B	$41.6B	$42.7B	$43.7B	$44.4B	$45.2B
Total liabilities	$17.1B	$17.4B	$17.7B	$18.9B	$19.1B	$19.2B	$18.2B	$20.0B
Long-term debt	$9.23B	$8.97B	$10.5B	$11.1B	$11.1B	$11.1B	$11.0B	$10.9B
Shareholders' equity	$20.7B	$21.8B	$22.2B	$22.4B	$23.4B	$24.2B	$25.9B	$24.9B
Cash flow
Operating cash flow	$1.00B	$1.46B	$541.0M	$1.29B	$1.34B	$1.36B	$348.0M	$1.47B
Capital expenditure	$179.0M	$277.0M	$187.0M	$157.0M	$181.0M	$351.0M	$177.0M	$195.0M
Free cash flow	$823.0M	$1.18B	$354.0M	$1.13B	$1.16B	$1.01B	$171.0M	$1.28B
Dividends paid	$0	$0	—	—	—	—	—	—

From Boston Scientific's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Boston Scientific vs the Health Care sector and the S&P 500

Boston Scientific's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Boston Scientific compared with the median Health Care company and the median S&P 500 company
Measure	Boston Scientific	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+19.9%	+7.1%	+7.0%
Net margin, latest fiscal year	14.4%	12.9%	12.9%
Share price change, 1 year	−54.7%	+22.8%	+7.5%

Boston Scientific: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Boston Scientific included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Boston Scientific

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Source: Wikipedia — Boston Scientific